The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Infectious Disease & AMR

Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
Editor's Choice

Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment

APR 8, 2026
Ferring Presents New Data Analyses for REBYOTA®
Infectious Disease & AMR

Ferring Presents New Data Analyses for REBYOTA®

NOV 4, 2025
Phagos Raises €25m Series A
Animal Health

Phagos Raises €25m Series A

OCT 10, 2025
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
Finance

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner

APR 29, 2025
Synthetic microbiome therapy suppresses bacterial infection without antibiotics
Basic & Discovery Research

Synthetic microbiome therapy suppresses bacterial infection without antibiotics

MAR 5, 2025
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
Finance

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

FEB 26, 2025
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Clinical & Manufacturing

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

JAN 27, 2025
Changes in microbiome predict risk for sexually transmitted disease
Basic & Discovery Research

Changes in microbiome predict risk for sexually transmitted disease

JAN 22, 2025
Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics
Infectious Disease & AMR

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics

DEC 17, 2024
SNIPR Biome receives up to €20 million European backing to advance therapies AMR
Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

DEC 10, 2024
A new simple and effective tool that recommends the best possible phage cocktail for a given patient
Infectious Disease & AMR

A new simple and effective tool that recommends the best possible phage cocktail for a given patient

NOV 28, 2024